|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Reducing Unin- teresting Spatial Association Rules in Geographic Databases U- sing Background Knowledge: A Summary of Results 显示文摘 | BOGORNY V KUIJPERS B ALVARES L O | 2008 | Int J Geogr Inf Sci2008，22，4： | 1 |
| 2 | Effect of microstructure on the tensile and fracture properties of sisal fiber/starch-based composite显示文摘 | Alvares V Vazquez A Bernal C | 2006 | Journal of Composite Materials2006，40，1： | 1 |
| 3 | Molecular recognition in the assembly of collagens:terminal noncollagenous domains are key recognition modules in the formation of triple helical protomers显示文摘 | Khoshnoodi J Cartaille J P Alvares K Arthur V Hudson B G | 2006 | J Biol Chem2006，281，38： | 1 |
| 4 | ST-DMQL:A semantic trajectory data mining query language显示文摘 | BOGORNY V KUIJPERS B ALVARES L O | 2009 | International Journal of Geographical Information Science2009，23，10： | 1 |
| 5 | Leishmaniasis worldwide and global estimates of its incidence 显示文摘 | Alvar J V e lez ID Bern C | 2012 | PLoS One2012，7，35： | 1 |
| 6 | Acute 1-arginine supplementation increases muscle blood volume but not strength performance显示文摘 | Alvares T S Conte C A Paschoalin V M | | 0，，01： | 1 |
| 7 | TGF-β1 actions on FRTL- 5cells provide a model for the physiological regulation of thyroid growth显示文摘 | Cameiro C Alvare'z C V Zalvide J | 1998 | Oncogene1998，16，11： | 1 |
| 8 | Towards se- mantic trajectory knowledge discovery显示文摘 | Alvares L O Bogorny V Kuijpers B | 2007 | Data Mining and Knowledge Discovery2007，，： | 1 |
| 9 | ST-DMQL: A se- mantic trajectory data mining Query language显示文摘 | Bogorny V Kuijpers B and Alvares L O | 2009 | Interna- tional Journal of Geographical Information Science2009，23，10： | 1 |
| 10 | What is the best biological treatment for rheumatoid arthritis? A systematic review of effectiveness显示文摘AIM:To evaluate the effectiveness of the biological disease-modifying antirheumatic drugs(b DMARD) in the treatment of rheumatoid arthritis through a systematic review of observational studies.METHODS:The studies were searched in the Pub Med,EMBASE,Cochrane Controlled Trials Register and LILACS databases(until August 2014),in the grey literature and conducted a manual search.The assessed criteria of effectiveness included the EULAR,the disease activity score(DAS),the Clinical Disease Activity Index,the Simplified Disease Activity Index,the American College of Rheumatology and the Health Assessment Questionnaire.The meta-analysis was performed with Review Manager 5.2 software using a random effects model.A total of 35 studies were included in this review.RESULTS:The participants anti-tumor necrosis factor inhibitors(TNF) nave,who used adalimumab(P = 0.0002) and etanercept(P = 0.0006) exhibited greater good EULAR response compared to the participants who used infliximab.No difference was detected between adalimumab and etanercept(P = 0.05).The participants who used etanercept exhibited greater remission according to DAS28 compared to the participants who used infliximab(P = 0.01).No differences were detected between adalimumab and infliximab(P = 0.12) or etanercept(P = 0.79).Better results were obtained with b DMARD associated with methotrexate than with b DMARD alone.The good EULAR response and DAS 28 was better for combination with methotrexate than b DMARD monotherapy(P = 0.03 e P < 0.00001).In cases of therapeutic failure,the participants who used rituximab exhibited greater DAS28 reduction compared to those who used anti-TNF agents(P = 0.0002).The participants who used etanercept achieved greater good EULAR response compared to those who did not use that drug(P = 0.007).Studies that assessed reduction of the CDAI score indicated the superiority of abatacept over rituximab(12.4 vs +1.7) and anti-TNF agents(7.6 vs 8.3).The present systematic review with meta-analysis found that relative to anti-TNF treatmentnave patients,adalimumab and etanercept were more effective when combined with methotrexate than when used alone.Furthermore,in case of therapeutic failure with anti-TNF agents;rituximab and abatacept(non anti-TNF) and etanercept(as second anti-TNF) were more effective.However,more studies of effectiveness were found for the rituximab.CONCLUSION:The best treatment for treatment-nave patients is adalimumab or etanercept combined with methotrexate.For anti-TNF therapeutic failure,the best choice is rituximab,abatacept or etanercept. | Jéssica Barreto dos Santos Juliana de Oliveira Costa Haliton Alves de Oliveira Junior Lívia Lovato Pires Lemos Vnia Eloisa de Araújo Marina Amaral de Avila Machado Alessandra Maciel Almeida Francisco de Assis Acurcio Juliana Alvares | 2015 | World Journal of Rheumatology2015，5，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员